

Armenia

Population 2015

3 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.092 (0.077–0.11)	3 (2.6–3.6)
Mortality (HIV+TB only)	0.014 (<0.01–0.074)	0.46 (0–2.4)
Incidence (includes HIV+TB)	1.2 (1.1–1.4)	41 (36–46)
Incidence (HIV+TB only)	0.11 (0.099–0.13)	3.7 (3.3–4.2)
Incidence (MDR/RR-TB)**	0.27 (0.2–0.34)	8.9 (6.6–11)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.054 (0.034–0.074)	0.27 (0.14–0.4)	0.32 (0.17–0.48)
Males	0.054 (0.038–0.07)	0.85 (0.67–1)	0.91 (0.71–1.1)
Total	0.11 (0.084–0.13)	1.1 (1–1.2)	1.2 (1.1–1.4)

TB case notifications, 2015	
Total cases notified	1 104
Total new and relapse	1 090
- % tested with rapid diagnostics at time of diagnosis	18%
- % with known HIV status	100%
- % pulmonary	72%
- % bacteriologically confirmed among pulmonary	45%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	89% (79–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.09 (0.05–0.13)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	99	9%
- on antiretroviral therapy	99	100%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			150 (130–180)
Estimated % of TB cases with MDR/RR-TB	11% (8–14)	47% (41–53)	
% notified tested for rifampicin resistance	0%	0%	436
MDR/RR-TB cases tested for resistance to second-line drugs			101
Laboratory-confirmed cases		MDR/RR-TB: 101, XDR-TB: 8	
Patients started on treatment ****		MDR/RR-TB: 168, XDR-TB: 8	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	78%	1 228
Previously treated cases, excluding relapse, registered in 2014	50%	14
HIV-positive TB cases, all types, registered in 2014	60%	77
MDR/RR-TB cases started on second-line treatment in 2013	43%	104
XDR-TB cases started on second-line treatment in 2013	20%	10

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	14%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	5.7
Funding source: 55% domestic, 45% international, 0% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence


— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse


— Retreatment, excluding relapse

— HIV-positive

— MDR/RR-TB

— XDR-TB

Total budget (US\$ millions)



— Unfunded

— Funded internationally

— Funded domestically